Ydsten, Karin A. published the artcileQuinacrine treatment of nitroimidazole-refractory giardiasis, Category: esters-buliding-blocks, the main research area is quinacrine nitroimidazole immunosuppression refractory giardiasis; adverse effects; epidemiology; giardiasis; nitroimidazole refractory; nitroimidazole resistance; quinacrine; tolerability; treatment.
Limited evidence exists on efficacy and tolerability of quinacrine for nitroimidazole-refractory giardiasis. Nitroimidazole-refractory giardiasis cases, defined as microbiol. (microscopy and/or PCR) confirmed treatment failure after 2 courses, during 2008-2020, were retrospectively identified. Of 87 patients, 54 (62%) had visited India. Quinacrine was used in 54 (62%); 51 received monotherapy and 3 combined with metronidazole. Only 3 had pos. stool samples with persisting symptoms after quinacrine treatment (94% parasitol. efficacy) and all were cured after a second treatment. One (1.9%) had mild adverse effects recorded. Quinacrine is an effective treatment for nitroimidazole-refractory giardiasis with good tolerability.
Journal of Infectious Diseases published new progress about Drug resistance. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Category: esters-buliding-blocks.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics